Anguita M, Arizón J M, Bueno G, Latre J M, Sancho M, Torres F, Giménez D, Concha M, Vallés F
Heart Transplantation Unit, Hospital Universitario Reina Sofía, Universidad de Córdoba, Spain.
Am J Cardiol. 1993 Aug 15;72(5):413-7. doi: 10.1016/0002-9149(93)91132-2.
To identify which clinical or hemodynamic parameters predict survival in patients with end-stage heart failure due to dilated cardiomyopathy, 130 consecutive patients aged < 65 years (mean 46 +/- 13) assessed for heart transplantation from May 1986 to April 1991 were studied. Mean follow-up was 15 +/- 11 months. Left ventricular ejection fraction was 22 +/- 7%. Left ventricular end-diastolic pressure was 27 +/- 9 mm Hg, and cardiac index was 2.2 +/- 0.6 liter/min/m2. Symptom class was IV in 91% of patients and III in 9%. Etiology was ischemic in 40% of patients and idiopathic in 60%. After intensive medical therapy, heart transplantation was considered indicated in 53% of patients, contraindicated in 20% and not indicated in 27%. Transplantation was performed in 36% of patients during follow-up, and 35% died and 29% were alive without transplantation. A comparison, excluding patients with transplantation, was performed between those who were alive and had survived > or = 6 months after assessment, and those who died. On multivariate analysis, the following 3 parameters were independent predictors of prognosis: intravenous inotropic requirement (p < 0.001), maximal, tolerated captopril dose (p = 0.013) and systolic blood pressure (p = 0.003). When patients with transplantation were considered as deaths, stabilization on medical therapy also reached statistical significance (p = 0.009). Classic prognostic markers including ventricular arrhythmias, left ventricular end-diastolic pressure, cardiac index, amiodarone therapy and etiology were not associated with prognosis in this homogeneous population of severely ill patients.
为了确定哪些临床或血流动力学参数可预测扩张型心肌病所致终末期心力衰竭患者的生存率,我们对1986年5月至1991年4月期间连续评估的130例年龄<65岁(平均46±13岁)的心脏移植患者进行了研究。平均随访时间为15±11个月。左心室射血分数为22±7%。左心室舒张末期压力为27±9 mmHg,心脏指数为2.2±0.6升/分钟/平方米。91%的患者症状分级为IV级,9%为III级。40%的患者病因是缺血性的,60%是特发性的。经过强化药物治疗后,53%的患者被认为适合进行心脏移植,20%为禁忌,27%不适合。在随访期间,36%的患者接受了移植,35%的患者死亡,29%的患者未移植存活。在排除移植患者后,对评估后存活且存活≥6个月的患者与死亡患者进行了比较。多因素分析显示,以下3个参数是预后的独立预测因素:静脉注射正性肌力药物的需求(p<0.001)、最大耐受卡托普利剂量(p = 0.013)和收缩压(p = 0.003)。当将移植患者视为死亡时,药物治疗的稳定情况也具有统计学意义(p = 0.009)。包括室性心律失常、左心室舒张末期压力、心脏指数、胺碘酮治疗和病因在内的经典预后标志物与这群病情严重的同质患者的预后无关。